| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Strategy Officer
1 company
Preethi Sundaram is Chief Strategy Officer at CPRX. Preethi Sundaram's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider.
Historically, Preethi Sundaram's trades have earned a middling insider score of 53/100 across 4 rated trades. Over a 12-month horizon, 66.7% of those trades were profitable, with an average 12-month return of +0.7%.
Preethi Sundaram has 15 Form 4 filings on record from September 2022 to December 2025, all as Chief Strategy Officer at Catalyst Pharmaceuticals (CPRX), 2022–2025.
The 33 reported transactions were 11 option exercises, 9 tax withholdings, 8 option or other derivative awards and 5 open-market sales.
Counted by filing, the open-market trades come to no purchases and 3 sales worth about $1.3M.
The largest open-market sale was 56,786 shares of CPRX at an average $16.38 on November 11, 2022, about $930K. Twelve months later CPRX was down 12%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 11, 2025 | CPRX Catalyst Pharmaceuticals, Inc. | Chief Strategy Officer | Sell | 3,924 | $26.41 | $103,648.84 | -8.7% | -21.3% | - | |
| Nov 11, 2022 | CPRX Catalyst Pharmaceuticals, Inc. | Chief Strategy Officer | Sale+OE | 56,786 | $16.38 | $929,870.75 | - | +5.7% | -12.3% | |
| Sep 15, 2022 | CPRX Catalyst Pharmaceuticals, Inc. | Chief Strategy Officer | Sale+OE | 18,214 | $14.49 | $263,920.86 | - | +30.0% | -8.5% |